Abstract
The CRASH-3 trial touted reduced mortality in patients with mild-to-moderate traumatic brain injury (TBI) who received tranexamic acid (TXA; NEJM JW
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have